Our MAGE-A10 T-cell therapy is directed to a highly immunogenic member of the MAGE-A family of cancer testis antigens expressed in a number of solid tumor cell types, and the immunogenicity of the MAGE-A10 antigen has been robustly established. Any expression in cancer is often associated with higher grade tumors.
Based on our ongoing preclinical evaluation, we believe our MAGE-A10 TCR therapeutic candidate has the potential ability to bind target peptides from multiple cancer types, including lung cancer. Clinical trials for our MAGE-A10 TCR therapy initiated in late 2015. The initial clinical program will be in patients with advanced stage NSCLC.